Email this article 
PERAN DULOXETINE DALAM KOMORBID NYERI DAN DEPRESI KRONIK
Abstract
Abstrak
Nyeri merupakan keluhan yang paling sering membawa pasien untuk mencari dokter. Nyeri kronik biasanya didefinisikan sebagai nyeri intermiten atau persisten yang berlangsung lebih dari 3 bulan. Nyeri kronik merupakan beban sosial maupun finansial baik bagi individu maupun negara. Nyeri kronik merupakan salah satu faktor penting yang menentukan adanya depresi. Hubungan dua arah komorbiditas nyeri kronik dan depresi sudah diketahui dengan baik, akan tetapi manajemen klinisnya sampai saat ini masih merupakan tantangan tersendiri. Pembahasan tentang duloxetine untuk manajemen komorbiditas nyeri kronik dan depresi masih belum diketahui dengan baik. Makalah kami akan membahas tentang duloxetine untuk manajemen komorbiditas nyeri kronik dan depresi.
Kata Kunci: nyeri kronik, depresi, faktor risiko, SNRI.
Abstract
Pain is the most common complaint making patients seeking the doctor. Chronic pain is usually defined as any intermittent or persistent pain that lasts more than 3 months. Chronic pain is a social and financial burden for both individuals or country. Chronic pain is one of the critical factors for determining depression. The bidirectional relationship between depression and chronic pain is well-recognized, but their clinical management remains challenging. The discussion about duloxetine for the management of comorbid chronic pain and depression is still not well understood. Our paper will discuss duloxetine for the management of comorbid chronic pain and depression.
Keywords: chronic pain, depression, risk factors, SNRIs
Keywords
Full Text:
PDFReferences
Zarei M, Tabatabaee A, Roshan Ravan M. The effect of wet-cupping on the severity of migraine headaches: Randomized controlled clinical trial. Biomed Res Ther. 2019;6(2):2992–5.
Gebke KB, McCarberg B, Shaw E, Turk DC, Wright WL, Semel D. A practical guide to recognize, assess, treat and evaluate (RATE) primary care patients with chronic pain. Postgrad Med [Internet]. 2021;00(00):1–10. Available from: https://doi.org/10.1080/00325481.2021.2017201
Dagnino APA, Campos MM. Chronic Pain in the Elderly: Mechanisms and Perspectives. Front Hum Neurosci. 2022;16:1–11.
Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet [Internet]. 2021;397(10289):2082–97. Available from: http://dx.doi.org/10.1016/S0140-6736(21)00393-7
Kremer M, Becker LJ, Barrot M, Yalcin I. How to study anxiety and depression in rodent models of chronic pain? Eur J Neurosci. 2021;53(1):236–70.
Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–82.
Balgah NP, Atanga MBS. Acute and Chronic Pain: Best Management Approaches in Resource Limited Setting, Cameroon. Pain Stud Treat. 2022;10(01):1–8.
Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast. 2017;2017.
Rapti E, Damigos D, Apostolara P, Roka V, Tzavara C, Lionis C. Patients with chronic pain: Evaluating depression and their quality of life in a single center study in Greece. BMC Psychol. 2019;7(1):1–11.
Banerjee N, DE R, Basu R. Chronic Pain and Depression: A Community Based Study in a Rural Area of West Bengal. J Clin Diagnostic Res. 2021;17–20.
Afrina R, Karimah A. Cognitive Behavioral Therapy for Chronic Pain. Biomol Heal Sci J. 2019;2(2):129.
Zheng CJ, Van Drunen S, Egorova-Brumley N. Neural correlates of co-occurring pain and depression: an activation-likelihood estimation (ALE) meta-analysis and systematic review. Transl Psychiatry. 2022;12(1):1–16.
Roughan WH, Campos AI, García-Marín LM, Cuéllar-Partida G, Lupton MK, Hickie IB, et al. Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness. Front Psychiatry. 2021;12(April):1–13.
Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Front Psychiatry. 2020;11(October).
BEHAVIORAL ASSESMENT OF THE PERIPHERAL NEUROPATHIC PAIN MODEL: RAT WITH CCI (CHRONIC CONSTRICTION INJURY).
Seth B, de Gray L. Genesis of chronic pain. Anaesth Intensive Care Med [Internet]. 2016;17(9):431–5. Available from: http://dx.doi.org/10.1016/j.mpaic.2016.06.011
Mills SEE, Nicolson KP, Smith BH. Chronic pain : a review of its epidemiology and associated factors in population-based studies. Br J Anaesth [Internet]. 2019;123(2):e273–83. Available from: https://doi.org/10.1016/j.bja.2019.03.023
Grünenwald I, Kaluza AJ, Schultze M, van Dick R. Stress Mindset and Social Identification in Chronic Pain Patients and Their Relationship to Coping, Well-Being & Depression. J Clin Psychol Med Settings [Internet]. 2022;(0123456789). Available from: https://doi.org/10.1007/s10880-022-09883-8
Kim S, Lee J, Boone D. Protective and Risk Factors at the Intersection of Chronic Pain, Depression, Anxiety, and Somatic Amplification: A Latent Profile Approach. J Pain Res. 2022;15:1107–21.
NCCN. Adult Cancer Pain Guidelines. Guidelines. 2016;
Ammitzbøll N, Arendt-Nielsen L, Bertoli D, Brock C, Olesen AE, Kappel A, et al. A mechanism-based proof of concept study on the effects of duloxetine in patients with painful knee osteoarthritis. Trials. 2021;22(1):1–11.
van den Driest JJ, Schiphof D, Koffeman AR, Koopmanschap MA, Bindels PJE, Bierma-Zeinstra SMA. No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A Cluster-Randomized Trial. Arthritis Rheumatol. 2022;74(5):818–28.
Murnion BP. Neuropathic pain: Current definition and review of drug treatment. Aust Prescr. 2018;41(3):60–3.
Cruccu G, Truini A. A review of Neuropathic Pain: From Guidelines to Clinical Practice. Pain Ther [Internet]. 2017;6(S1):35–42. Available from: http://link.springer.com/10.1007/s40122-017-0087-0
Kessler TL, Brooks KG. Treatments for neuropathic pain. Clin Pharm. 2017;9(12):1–16.
Practice C. Neuropathic pain – pharmacological management The pharmacological management of neuropathic pain in adults in. NICE clinical guideline 173. http://guidance.nice.org.uk/CG173. 2013.
Lisinski A, Hieronymus F. Item-based analysis of the effects of duloxetine in depression : a patient-level post hoc study. Neuropsychopharmacology [Internet]. 2019;(September). Available from: http://dx.doi.org/10.1038/s41386-019-0523-4
Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O’Brien T, Mercadante S, et al. Standards for the management of cancer-related pain across Europe—A position paper from the EFIC Task Force on Cancer Pain. Eur J Pain (United Kingdom). 2019;23(4):660–8.
Mpt L, Rac H, Pj W. Duloxetine for treating painful neuropathy or chronic pain ( Review ). Cochrane Libr. 2011;(4).
DOI: https://doi.org/10.32539/JKK.V10I3.22063
Refbacks
- There are currently no refbacks.
E-ISSN (Online) : 2614-0411
Jl. Dr. Moehammad Ali Kompleks RSMH Palembang 30126, Indonesia
Telp. 0711-352342, Fax.: 0711-373438
email: jurnalfkunsri@gmail.com
Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya by https://ejournal.unsri.ac.id/index.php/jkk is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.